We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Acadia Healthcare (ACHC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Acadia Healthcare is a member of our Medical group, which includes 915 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Acadia Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACHC's full-year earnings has moved 2.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACHC has returned about 145.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 8.3% on a year-to-date basis. This means that Acadia Healthcare is outperforming the sector as a whole this year.
Aclaris Therapeutics (ACRS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 19.9%.
The consensus estimate for Aclaris Therapeutics' current year EPS has increased 1.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Acadia Healthcare belongs to the Medical - Hospital industry, a group that includes 4 individual companies and currently sits at #193 in the Zacks Industry Rank. On average, stocks in this group have gained 19.7% this year, meaning that ACHC is performing better in terms of year-to-date returns.
On the other hand, Aclaris Therapeutics belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #104. The industry has moved -4.6% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Acadia Healthcare and Aclaris Therapeutics as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Acadia Healthcare (ACHC - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Acadia Healthcare is a member of our Medical group, which includes 915 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Acadia Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ACHC's full-year earnings has moved 2.5% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ACHC has returned about 145.2% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 8.3% on a year-to-date basis. This means that Acadia Healthcare is outperforming the sector as a whole this year.
Aclaris Therapeutics (ACRS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 19.9%.
The consensus estimate for Aclaris Therapeutics' current year EPS has increased 1.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Acadia Healthcare belongs to the Medical - Hospital industry, a group that includes 4 individual companies and currently sits at #193 in the Zacks Industry Rank. On average, stocks in this group have gained 19.7% this year, meaning that ACHC is performing better in terms of year-to-date returns.
On the other hand, Aclaris Therapeutics belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #104. The industry has moved -4.6% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Acadia Healthcare and Aclaris Therapeutics as they could maintain their solid performance.